William Patalon IIIGet Bill Patalon's latest recommendations sent straight to your inbox the moment they're released.
Coinbase's massive IPO means cryptocurrencies have "officially" arrived on Wall Street.
It's an extremely bullish development for Bitcoin, but… investors everywhere want to know about the exchange's stock itself – "Should I buy Coinbase?"
Here's what you need to know…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Our Bill Patalon recently had a conversation with Money Morning's Director of Cannabis Investing Research, Don Yocham, about the monster rally in cannabis stocks sparked by the Democratic sweep of the White House and Congress.
He's sharing all the critical points of their chat with you, plus a winning cannabis play…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Our Bill Patalon recently sat down to a virtual interview with our resident Bitcoin expert David Zeiler, who’s predicting six-figure BTC prices by 2022.
What’s more, he’s called it right since 2016.
Read the full interview right here – you don’t want to miss it….
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
There's a "New Cold War" underway right now, and it's heating up.
Investors can't afford to ignore a $2 trillion global business: Defense.
And understanding where defense dollars will be spent will help you zero in on the winners in the "New Arms Race" – while also avoiding sectors and firms that'll be left behind.
Here's how to get started….
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
China’s recently adopted an anti-innovation stance with strict implications on its businesses, such as e-commerce giant Alibaba.
But that does NOT mean to dump Alibaba shares.
Instead, Bill Patalon will have us cashing in on this “one-stock wealth machine” no matter what China does next….
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Back on Aug. 20, a U.S. Air Force pilot climbed into an F-16 "simulator" – in essence, a digital copy that does everything a real Lockheed Martin Fighting Falcon can do – and squared off in a "dogfight" against an artificial intelligence robot.
The result: The AI robot shot the human pilot down in flames.
Digitally speaking, of course.
The shoot-down of a human F-16 pilot was part of a multi-day dogfight competition sponsored by the Defense Advanced Research Projects Agency (DARPA). In fact, it played out in the grand finale of that DARPA "Air Combat Evolution" (ACE) competition – and meant that an AI "algorithm" was crowned as champ.
A robot is America's Top Gun.
It's a next key step in the "Drones Revolution" I've been chronicling for my Private Briefing subscribers.
And for investors like you, it means a hefty "wealth window" has been pushed wide open.
We're talking total "Blue Sky" profits… Full Story
We're talking total "Blue Sky" profits...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Bill recommended this "value" stock to his subscribers way back in 2013, but Wall Street is just catching on. If you were following along, you're way ahead of Wall Street.
And even if you weren't, that's okay, too, because it's not too late to get in on this stock.
With all the attention on it, it still has plenty of room to grow...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
"The best defense is a good offense."
– Boxer Jack Dempsey
I've always loved this Jack Dempsey quote – and with good reason.
It tells us that, when the chips are down, you don't sit back, "go defensive," and let events take control over you.
Instead, you take control. You go on the attack. You go on the offensive.
You adopt what I like to call an "offensive/defensive" investing strategy.
In today's "disruption economy" – where innovation keeps changing the competitive landscape – that's the only way to go.
And in today's issue of Money Morning, we're going to show you how this flavor of "defensive investing" can help you navigate this volatile pandemic market… Full Story
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
"The journey of a thousand miles begins with a single step."
– Chinese proverb attributed to philosopher Laozi
With all the COVID-19 whipsawing we're experiencing in the U.S. economy – and the uncertainty that's created for folks like you and me – Money Map Press is seeing more direct inquiries about stocks than at any time since the Great Financial Crisis of 2008 to 2009.
And one of the most intriguing queries we're seeing is this one: "I have $2,000. I want to invest it in stocks. But I'd sure be grateful for some guidance on which stocks to buy and what 'strategy' to employ."
Let me tell you folks: I love this question.
And I respect the heck out of those who posed it, or who were thinking along those lines, for a few reasons…
For one, you're ignoring the near-term "noise" and are focusing on the long term.
Second, you're taking action – and taking control of your own financial destiny – which is always one heck of a lot better than just sitting back and letting stuff "happen to you."
And, finally, it can be a difference-maker. That two grand is merely the first step. But it shows that you're serious about changing your future. It puts "skin in the game." It forces you to pay attention. And you'll be stunned at how much you learn.
It takes courage to act, to make tough decisions, to move forward.
And by posing this question, you're doing just that.
Just as a long journey can start with a single step, the journey toward a secure financial future can begin with a single investment – even one as seemingly small as $2,000.
And I'm going to start by sharing a personal story that proves the value of a "mere" $2,000 investment. I'll even offer some stock recommendations that will help you take that first step… Full Story
Start the conversation